{"id":523884,"date":"2021-08-05T07:05:30","date_gmt":"2021-08-05T11:05:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/"},"modified":"2021-08-05T07:05:30","modified_gmt":"2021-08-05T11:05:30","slug":"landos-biopharma-to-participate-in-upcoming-investor-events","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/","title":{"rendered":"Landos Biopharma to Participate in Upcoming Investor Events"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BLACKSBURG, Va., Aug.  05, 2021  (GLOBE NEWSWIRE) &#8212; Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE<sup>\u00ae<\/sup> Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos and additional management team members will participate in the following investor events in August.<\/p>\n<p>\n        <strong>Event:<\/strong> BTIG Virtual Biotechnology Conference <br \/><strong>Date:<\/strong> August 9-10, 2021<br \/><strong>Format: <\/strong>Virtual<br \/><strong>Presentation:<\/strong> Tuesday, August 10, 2021 at 3:00 p.m. EDT<\/p>\n<p>\n        <strong>Event:<\/strong> Canaccord Genuity 41<sup>st<\/sup> Annual Growth Conference <br \/><strong>Date:<\/strong> August 10-12, 2021<br \/><strong>Format: <\/strong>Virtual<br \/><strong>Presentation:<\/strong> Wednesday, August 11, 2021 at 10:30 a.m. ET<\/p>\n<p>\n        <strong>Event:<\/strong> BMO BioPharma Spotlight Series: Innovation in GI <br \/><strong>Date:<\/strong> August 12, 2021<br \/><strong>Format: <\/strong>Virtual<br \/><strong>Presentation:<\/strong> Thursday, August 12, 2021 at 10:50 a.m. ET<\/p>\n<p>\n        <strong>Event:<\/strong> Solebury Trout Annual Hamptons CEO Roundtable<br \/><strong>Date:<\/strong> August 12, 2021<br \/><strong>Format: <\/strong>In-person<br \/><strong>Presentation:<\/strong> Thursday, August 12, 2021 at 11:30 a.m. ET<br \/><strong>Location<\/strong>: Topping Rose House, Bridgehampton, NY<\/p>\n<p>Management team will also meet with investors throughout these events. Investors interested in meeting with the Landos Biopharma management team during these events should contact their respective representatives or Marek Ciszewski, VP of Financial Strategy and Investor Relations at Landos: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2LZhLOosdw2rlYwJO0SHOg_YREPnI6TBxhsS5KHgCarOYpyknVXqWVN1rJiNLvq5FF0q_psohhwXFQbaiiEgw8FpikA84-c-_6OQuZucVrk=\" rel=\"nofollow noopener\" target=\"_blank\">Marek@LandosBiopharma.com<\/a>.<\/p>\n<p>Where available, a live webcast and subsequent archive of the presentations will be accessible through the Investors\/Media section of the Company\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QK1aYP-GXVBc6v66PVtX9el48ZR2foB4ecwx1yIJkyDAwfQpHy8xkdj0vE1f2qYIXtPJjI2F8_TGaBlsqs3UvMJs9yNm-45aCiXsmo_098k=\" rel=\"nofollow noopener\" target=\"_blank\">www.landosbiopharma.com<\/a>.<\/p>\n<p>\n        <strong>About Landos Biopharma<\/strong><br \/>\n        <br \/>Landos Biopharma is a late-clinical-stage biopharmaceutical company utilizing its LANCE<sup>\u00ae<\/sup>\u00a0Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases. LANCE has discovered new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma has 17 active development programs targeting these novel pathways at the interface of immunity and metabolism. Lead asset omilancor is a novel gut-restricted small molecule drug candidate for the treatment of ulcerative colitis, Crohn\u2019s disease, Eosinophilic Esophagitis and, in topical formulation, for psoriasis and atopic dermatitis that targets the LANCL2 pathway. NX-13 is a novel, gut-restricted small molecule drug candidate for the treatment of inflammatory bowel disease, that targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QK1aYP-GXVBc6v66PVtX9el48ZR2foB4ecwx1yIJkyBCFdWAlR7wZR94IJNuEA4wk01qo8hNY_2yprCnbKW2Ii9CIRRJn14Y57ho7QcNd7Y=\" rel=\"nofollow noopener\" target=\"_blank\">www.landosbiopharma.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Michael K. Levitan (investors)<br \/>Solebury Trout<br \/>646-378-2920<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qaI_QXyE6oQIYEnXhSMOrQbk2M-JZgzCoBVY2y50r6a6VWfFoWli1hN7WXHszA5NrF1OVtHjkhQ79XLAGoVisUZ6BBzAcu7qHbpwE-aRT4r1M1_usl4n8urkgqoOaBC8\" rel=\"nofollow noopener\" target=\"_blank\">mlevitan@soleburytrout.com<\/a><\/p>\n<p>Hannah Gendel (media)<br \/>Solebury Trout<br \/>646-378-2943<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AVbwC0g6q7H1sGHLGM8rIjjJ5o3jS-uFzoXjertZqfXRtS28Jw8m4wD1MrhCSsSkmHENC7u-6fdBIXPyg4JOzaqjvg02FLY1Af-SwJUXVy4=\" rel=\"nofollow noopener\" target=\"_blank\">hgendel@soleburytrout.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzExNiM0MzQyMzI1IzIxODg5NDg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/23372d74-bfb8-4309-9631-57a7112a0f7f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) &#8212; Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE\u00ae Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos and additional management team members will participate in the following investor events in August. Event: BTIG Virtual Biotechnology Conference Date: August 9-10, 2021Format: VirtualPresentation: Tuesday, August 10, 2021 at 3:00 p.m. EDT Event: Canaccord Genuity 41st Annual Growth Conference Date: August 10-12, 2021Format: VirtualPresentation: Wednesday, August 11, 2021 at 10:30 a.m. ET Event: BMO BioPharma Spotlight Series: Innovation in GI Date: August 12, 2021Format: VirtualPresentation: Thursday, August 12, 2021 at 10:50 a.m. ET Event: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Landos Biopharma to Participate in Upcoming Investor Events&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-523884","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Landos Biopharma to Participate in Upcoming Investor Events - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Landos Biopharma to Participate in Upcoming Investor Events - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) &#8212; Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE\u00ae Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos and additional management team members will participate in the following investor events in August. Event: BTIG Virtual Biotechnology Conference Date: August 9-10, 2021Format: VirtualPresentation: Tuesday, August 10, 2021 at 3:00 p.m. EDT Event: Canaccord Genuity 41st Annual Growth Conference Date: August 10-12, 2021Format: VirtualPresentation: Wednesday, August 11, 2021 at 10:30 a.m. ET Event: BMO BioPharma Spotlight Series: Innovation in GI Date: August 12, 2021Format: VirtualPresentation: Thursday, August 12, 2021 at 10:50 a.m. ET Event: &hellip; Continue reading &quot;Landos Biopharma to Participate in Upcoming Investor Events&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-05T11:05:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzExNiM0MzQyMzI1IzIxODg5NDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/landos-biopharma-to-participate-in-upcoming-investor-events\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/landos-biopharma-to-participate-in-upcoming-investor-events\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Landos Biopharma to Participate in Upcoming Investor Events\",\"datePublished\":\"2021-08-05T11:05:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/landos-biopharma-to-participate-in-upcoming-investor-events\\\/\"},\"wordCount\":382,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/landos-biopharma-to-participate-in-upcoming-investor-events\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMzExNiM0MzQyMzI1IzIxODg5NDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/landos-biopharma-to-participate-in-upcoming-investor-events\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/landos-biopharma-to-participate-in-upcoming-investor-events\\\/\",\"name\":\"Landos Biopharma to Participate in Upcoming Investor Events - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/landos-biopharma-to-participate-in-upcoming-investor-events\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/landos-biopharma-to-participate-in-upcoming-investor-events\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMzExNiM0MzQyMzI1IzIxODg5NDg=\",\"datePublished\":\"2021-08-05T11:05:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/landos-biopharma-to-participate-in-upcoming-investor-events\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/landos-biopharma-to-participate-in-upcoming-investor-events\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/landos-biopharma-to-participate-in-upcoming-investor-events\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMzExNiM0MzQyMzI1IzIxODg5NDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMzExNiM0MzQyMzI1IzIxODg5NDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/landos-biopharma-to-participate-in-upcoming-investor-events\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Landos Biopharma to Participate in Upcoming Investor Events\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Landos Biopharma to Participate in Upcoming Investor Events - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/","og_locale":"en_US","og_type":"article","og_title":"Landos Biopharma to Participate in Upcoming Investor Events - Market Newsdesk","og_description":"BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) &#8212; Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE\u00ae Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos and additional management team members will participate in the following investor events in August. Event: BTIG Virtual Biotechnology Conference Date: August 9-10, 2021Format: VirtualPresentation: Tuesday, August 10, 2021 at 3:00 p.m. EDT Event: Canaccord Genuity 41st Annual Growth Conference Date: August 10-12, 2021Format: VirtualPresentation: Wednesday, August 11, 2021 at 10:30 a.m. ET Event: BMO BioPharma Spotlight Series: Innovation in GI Date: August 12, 2021Format: VirtualPresentation: Thursday, August 12, 2021 at 10:50 a.m. ET Event: &hellip; Continue reading \"Landos Biopharma to Participate in Upcoming Investor Events\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-05T11:05:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzExNiM0MzQyMzI1IzIxODg5NDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Landos Biopharma to Participate in Upcoming Investor Events","datePublished":"2021-08-05T11:05:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/"},"wordCount":382,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzExNiM0MzQyMzI1IzIxODg5NDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/","name":"Landos Biopharma to Participate in Upcoming Investor Events - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzExNiM0MzQyMzI1IzIxODg5NDg=","datePublished":"2021-08-05T11:05:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzExNiM0MzQyMzI1IzIxODg5NDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMzExNiM0MzQyMzI1IzIxODg5NDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/landos-biopharma-to-participate-in-upcoming-investor-events\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Landos Biopharma to Participate in Upcoming Investor Events"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/523884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=523884"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/523884\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=523884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=523884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=523884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}